Brief: Silo Pharma’S Ptsd Program Advances As FDA Fast-Tracks Psychedelic Therapies For Ptsd
29/04/2026 14:16
April 29 (Reuters) - Silo Pharma Inc SILO.O: SILO PHARMA’S PTSD PROGRAM ADVANCES AS FDA FAST-TRACKS PSYCHEDELIC THERAPIES FOR PTSD SILO PHARMA INC - FDA GRANTS IND CLEARANCE TO DEMERX NB FOR NORIBOGAINE TARGETING ALCOHOL USE DISORDER Source text: ID:nGNX7R6gS Further company coverage: SILO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Silo Pharma
See all newsBrief: Silo Pharma - Enters Asset Purchase Agreement With Larry King On October 13, 2026 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Norsight Consulting On Oct 1 - SEC Filing
Brief: Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting
Brief: Silo Pharma Selling Shareholders Offer On Resale Basis 1.9 Million Shares Of Silo Pharma Common Stock - SEC Filing
Brief: Silo Pharma Regains Compliance With Nasdaq Minimum Bid Price Requirement